Aliases & Classifications for Mumps

MalaCards integrated aliases for Mumps:

Name: Mumps 12 76 53 55 43 3 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10264
ICD10 33 B26 B26.9 B26.8
ICD9CM 35 072
MeSH 44 D009107
NCIt 50 C29888
UMLS 73 C0026780

Summaries for Mumps

MedlinePlus : 43 Mumps is an illness caused by the mumps virus. It starts with Fever Headache Muscle aches Tiredness Loss of appetite After that, the salivary glands under the ears or jaw become swollen and tender. The swelling can be on one or both sides of the face. Symptoms last 7 to 10 days. Serious complications are rare. You can catch mumps by being with another person who has it. There is no treatment for mumps, but the measles-mumps-rubella (MMR) vaccine can prevent it. Before the routine vaccination program in the United States, mumps was a common illness in infants, children and young adults. Now it is a rare disease in the U.S. Centers for Disease Control and Prevention

MalaCards based summary : Mumps is related to primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection and rubella, and has symptoms including fever, headache and muscle aches. An important gene associated with Mumps is STAT2 (Signal Transducer And Activator Of Transcription 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include salivary gl, salivary gland and heart, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

CDC : 3 Mumps is a contagious disease caused by a virus. It typically starts with a few days of fever, headache, muscle aches, tiredness, and loss of appetite, followed by swollen salivary glands. You can protect yourself and your family against mumps with vaccination.

Disease Ontology : 12 A viral infectious disease that results in inflammation located in salivary gland, has material basis in Mumps virus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face.

Wikipedia : 76 Mumps is a viral disease caused by the mumps virus. Initial signs and symptoms often include fever,... more...

Related Diseases for Mumps

Diseases in the Mumps family:

Congenital Mumps

Diseases related to Mumps via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 283)
# Related Disease Score Top Affiliating Genes
1 primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection 34.3 IFNAR2 STAT2
2 rubella 31.0 CD40LG HLA-DRB1 IFNAR2 IL10RB TNF
3 meningitis 30.2 CD40LG IFNG TNF
4 measles 30.1 CD40LG CD46 IFNAR2 IFNG IL2 STAT1
5 recurrent respiratory papillomatosis 29.5 HLA-DRB1 IL2
6 hepatitis b 29.4 IFNAR2 IFNG IL10RB TNF
7 central nervous system disease 29.1 CD40LG IFNG TNF
8 q fever 29.1 CD40LG IFNG TNF
9 tetanus 29.1 CD40LG IFNG IL2
10 toxoplasmosis 29.0 CD40LG IFNG TNF
11 chlamydia 29.0 CD40LG IFNG TNF
12 nervous system disease 29.0 CD40LG IFNG TNF
13 posterior uveitis 28.6 IFNG IL2 TNF
14 rheumatic disease 28.6 CD40LG HLA-DRB1 IFNG TNF
15 exanthem 28.4 CD40LG IL2 TNF
16 human immunodeficiency virus type 1 27.9 IFNG IL2 STAT1 TNF
17 multiple sclerosis 27.2 HLA-DRB1 IFNG IL2 STAT1 TNF TNFRSF1A
18 inflammatory bowel disease 25.1 HLA-DRB1 IFNG IL10RB IL12RB2 IL2 STAT1
19 congenital mumps 12.0
20 acute disseminated encephalomyelitis 11.3
21 endotheliitis 11.2
22 testicular microlithiasis 10.8
23 infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovascular malformations 10.8
24 immunodeficiency 45 10.8
25 male infertility 10.8
26 salivary gland disease 10.8
27 immune-mediated encephalomyelitis 10.8
28 postinfectious encephalomyelitis 10.8
29 axillary adenitis 10.6 CD40LG STAT1
30 zika fever 10.5 CD40LG STAT1
31 microscopic polyangiitis 10.5 HLA-DRB1 TNF
32 chronic gonococcal salpingitis 10.5 TNF TNFRSF1A
33 beryllium disease 10.4 HLA-DRB1 TNF
34 histoplasmosis 10.4 HLA-DRB1 IFNG STAT1
35 staphylococcal toxic shock syndrome 10.4 IFNG TNF
36 orchitis 10.4
37 autoimmune pancreatitis 10.3 HLA-DRB1 TNF
38 aseptic meningitis 10.3
39 rabies 10.3 CD40LG STAT1 STAT2
40 palindromic rheumatism 10.3 HLA-DRB1 TNF TNFRSF1A
41 aging 10.3
42 parotitis 10.3
43 trichosporonosis 10.2 IFNG TNF
44 coccidioidomycosis 10.2 CD40LG STAT1
45 african tick-bite fever 10.2 CD40LG IFNG
46 cat-scratch disease 10.2 CD40LG IFNG
47 trench fever 10.2 CD40LG TNF
48 encephalitozoonosis 10.2 CD40LG TNF
49 rheumatoid lung disease 10.2 CD40LG TNF
50 anca-associated vasculitis 10.2 HLA-DRB1 TNF

Graphical network of the top 20 diseases related to Mumps:



Diseases related to Mumps

Symptoms & Phenotypes for Mumps

Symptoms:

12
  • fever
  • headache
  • muscle aches
  • tiredness
  • loss of appetite
  • swollen

UMLS symptoms related to Mumps:


fever, pruritus

GenomeRNAi Phenotypes related to Mumps according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.7 STAT1 TNF TNFRSF1A CD40LG IL2 RIPK1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.7 STAT1 TNF TNFRSF1A CD40LG IL2 RIPK1

MGI Mouse Phenotypes related to Mumps:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 IFNG IRAK1 IL10RB CD40LG IL12RB2 IFNAR2
2 cardiovascular system MP:0005385 10.15 IL2 IFNG IRAK1 CD40LG CD46 IL12RB2
3 cellular MP:0005384 10.13 IL2 IFNG IRAK1 IL10RB CD40LG STAT1
4 immune system MP:0005387 10.13 IL2 IFNG IRAK1 IL10RB CD40LG IL12RB2
5 endocrine/exocrine gland MP:0005379 10.09 IL2 IFNG IL10RB CD40LG IL12RB2 STAT1
6 homeostasis/metabolism MP:0005376 10.07 IFNAR2 IL2 IFNG IL10RB CD40LG IL12RB2
7 digestive/alimentary MP:0005381 10.06 IL2 IFNG IL10RB IL12RB2 TNF RIPK1
8 integument MP:0010771 9.8 IFNG CD40LG STAT1 IRF2 TNF RIPK1
9 liver/biliary system MP:0005370 9.76 IL2 IFNG IL10RB IL12RB2 TNF RIPK1
10 mortality/aging MP:0010768 9.73 IL2 IFNG IRAK1 IL10RB CD40LG IFNAR2
11 neoplasm MP:0002006 9.17 IL2 IFNG IL12RB2 IFNAR2 TNF TNFRSF1A

Drugs & Therapeutics for Mumps

Drugs for Mumps (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
2 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
5 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Not Applicable
6 Liver Extracts Phase 4
7
Tetracycline Approved, Vet_approved Phase 3,Phase 2 60-54-8 5353990
8
Aluminum hydroxide Approved, Investigational Phase 3,Phase 2 21645-51-2
9
Hydroxocobalamin Approved Phase 3 13422-51-0 11953898 44475014
10
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
11
Lactitol Investigational Phase 3,Phase 2 585-86-4 3871
12 Anti-Bacterial Agents Phase 3,Phase 2
13 Anti-Infective Agents Phase 3,Phase 2
14 Vitamin B 12 Phase 3
15 PENTA Phase 3,Phase 2
16
Cobalamin Nutraceutical Phase 3 13408-78-1 6438156
17 Vitamin B12 Nutraceutical Phase 3
18
Altretamine Approved Phase 2 645-05-6 2123
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
20
Mycophenolate mofetil Approved, Investigational Phase 2 128794-94-5 5281078
21
Mycophenolic acid Approved Phase 2 24280-93-1 446541
22
Obinutuzumab Approved, Investigational Phase 2,Phase 1 949142-50-1
23
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
24
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
25
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
26
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
27 Anticoagulants Phase 2
28 Fibrinolytic Agents Phase 2
29 Antibodies, Monoclonal Phase 2,Not Applicable
30 Immunoglobulin G Phase 2
31 Immunosuppressive Agents Phase 2,Not Applicable
32 Interleukin-2 Phase 2
33 Peripheral Nervous System Agents Phase 2
34 Antibiotics, Antitubercular Phase 2
35 Antiemetics Phase 2
36 Anti-Inflammatory Agents Phase 2
37 Antineoplastic Agents, Hormonal Phase 2
38 Antitubercular Agents Phase 2
39 Autonomic Agents Phase 2
40 Gastrointestinal Agents Phase 2
41 glucocorticoids Phase 2
42 Hormone Antagonists Phase 2
43 Hormones Phase 2
44 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
45 Methylprednisolone acetate Phase 2
46 Methylprednisolone Hemisuccinate Phase 2
47 Neuroprotective Agents Phase 2
48 Prednisolone acetate Phase 2
49 Prednisolone hemisuccinate Phase 2
50 Prednisolone phosphate Phase 2

Interventional clinical trials:

(show top 50) (show all 144)
# Name Status NCT ID Phase Drugs
1 The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine Unknown status NCT02153866 Phase 4
2 Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations Completed NCT01777529 Phase 4
3 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine Completed NCT02880865 Phase 4
4 Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Completed NCT00731965 Phase 4
5 Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00126997 Phase 4
6 Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR Completed NCT02325310 Phase 4
7 Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine Completed NCT03160820 Phase 4
8 Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine Completed NCT00313950 Phase 4
9 MMR Vaccination Among HIV-infected Adults Completed NCT02724852 Phase 4
10 Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Completed NCT00326183 Phase 4
11 Concomitant Use of Hepatitis A Vaccine With Measles, Mumps, Rubella and Varicella Vaccine and Pneumococcal 7-Valent Conjugate Vaccine in Healthy 12-Month-Old Children (V251-067) Completed NCT00312858 Phase 4
12 Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. Completed NCT00388440 Phase 4
13 Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children Completed NCT02253407 Phase 4
14 Safety Study of a Refrigerator-stable Formulation of VARIVAX® Completed NCT00432731 Phase 4
15 Study of the Influence of Vaccination in HIV Viral Load and Immunologic Responses Against HIV Completed NCT00329251 Phase 4
16 Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts Recruiting NCT03183765 Phase 4 Measles-Mumps-Rubella Vaccine
17 Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines Recruiting NCT03368495 Phase 4
18 Homeopathic Vaccine Trial Recruiting NCT02825368 Phase 4
19 Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients Recruiting NCT01770119 Phase 4
20 Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination Not yet recruiting NCT03350698 Phase 4
21 Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants Unknown status NCT01763268 Phase 2, Phase 3
22 Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants Completed NCT02692599 Phase 3
23 Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older Completed NCT02058563 Phase 3
24 A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) Completed NCT00092391 Phase 3
25 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127023 Phase 3
26 Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases Completed NCT00127010 Phase 3
27 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed NCT01188343 Phase 3
28 Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) Completed NCT01536405 Phase 3
29 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life Completed NCT01681992 Phase 3
30 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
31 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age Completed NCT02184572 Phase 3
32 Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) Completed NCT00092430 Phase 3
33 Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 Completed NCT00751348 Phase 3
34 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age Completed NCT01621802 Phase 3
35 Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) Completed NCT00432042 Phase 3
36 Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age Completed NCT01702428 Phase 3
37 Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children Completed NCT00192491 Phase 3
38 Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children Completed NCT01506193 Phase 3
39 Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM Completed NCT00969436 Phase 3
40 Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children Completed NCT00197015 Phase 3
41 ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) Completed NCT00975507 Phase 3
42 Safety Study of ProQuad® rHA in Infants (V221-037) Completed NCT00560755 Phase 3
43 Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox Completed NCT00226499 Phase 3
44 Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers Completed NCT00422292 Phase 3
45 A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) Completed NCT00985166 Phase 3
46 Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine Completed NCT00406211 Phase 3
47 Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) Completed NCT00985153 Phase 3
48 ProQuad® Intramuscular vs Subcutaneous Completed NCT00402831 Phase 3
49 Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) Completed NCT00566527 Phase 3
50 Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route Completed NCT00432523 Phase 3

Search NIH Clinical Center for Mumps

Cochrane evidence based reviews: mumps

Genetic Tests for Mumps

Anatomical Context for Mumps

The Foundational Model of Anatomy Ontology organs/tissues related to Mumps:

19
Salivary Gl

MalaCards organs/tissues related to Mumps:

41
Salivary Gland, Heart, Testes, Liver, B Cells, Skin, T Cells

Publications for Mumps

Articles related to Mumps:

(show top 50) (show all 868)
# Title Authors Year
1
Therapeutic Outcome of Intralesional Immunotherapy in Cutaneous Warts Using the Mumps, Measles, and Rubella Vaccine: A Randomized, Placebo-controlled Trial. ( 29785233 )
2018
2
Knowledge gaps persist and hinder progress in eliminating mumps. ( 29784466 )
2018
3
Genomic non-coding regions reveal hidden patterns of mumps virus circulation in Spain, 2005 to 2015. ( 29667574 )
2018
4
Mumps: A Pain in the Neck. ( 29718326 )
2018
5
Assessment of mumps-containing vaccine effectiveness during an outbreak: Importance to introduce the 2-dose schedule for China. ( 29377772 )
2018
6
Impact of meteorological factors on mumps and potential effect modifiers: An analysis of 10 cities in Guangxi, Southern China. ( 29966878 )
2018
7
Resurgence risk for measles, mumps and rubella in France in 2018 and 2020. ( 29945697 )
2018
8
Non-mumps Viral Parotitis During the 2014-2015 Influenza Season in the United States. ( 29617951 )
2018
9
Prevalence of Inadequate Immunity to Measles, Mumps, Rubella, and Varicella in MLB and NBA Athletes. ( 29792776 )
2018
10
Utility of neutralization test for the laboratory diagnosis of suspected mumps cases. ( 29363797 )
2018
11
Mumps disease in Beijing in the era of two-dose vaccination policy, 2005-2016. ( 29653850 )
2018
12
Recognizing Measles, Mumps, and Rubella in the Emergency Department. ( 29715253 )
2018
13
Polymorphisms in the Wilms Tumor Gene Are Associated With Interindividual Variations in Rubella Virus-Specific Cellular Immunity After Measles-Mumps-Rubella II Vaccination. ( 29253144 )
2018
14
An outbreak due to mumps virus genotype G in a tribal population during 2016-17 from India. ( 29873412 )
2018
15
Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7A years of age or older: a phaseA III, randomized study. ( 29902133 )
2018
16
Application of a mixture model to assess the effect of measles-mumps-rubella vaccine on the mumps epidemic in children from kindergarten to early school age in Jiangsu Province, China. ( 29792546 )
2018
17
Pharyngolaryngeal edema in mumps virus infection: Rare complication. ( 29878635 )
2018
18
Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial. ( 29395526 )
2018
19
Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine. ( 29317117 )
2018
20
Mumps outbreaks: A problem in need of solutions. ( 29678496 )
2018
21
Meteorological factors and the incidence of mumps in Fujian Province, China, 2005-2013: Non-linear effects. ( 29734606 )
2018
22
Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. ( 29324728 )
2018
23
Acute Motor Axonal Polyneuropathy Following Mumps Infection in a 9-Year-Old Girl. ( 29669036 )
2018
24
Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation. ( 29426830 )
2018
25
Implementation of molecular techniques for diagnosis of mumps. ( 29789179 )
2018
26
Mumps infection but not childhood vaccination induces persistent polyfunctional CD8<sup>+</sup>T-cell memory. ( 29339261 )
2018
27
Laboratory testing and phylogenetic analysis during a mumps outbreak in Ontario, Canada. ( 29866178 )
2018
28
Assessment of Humoral Immunity to Hepatitis B, Measles, Rubella, and Mumps in Children After Chemotherapy. ( 29309372 )
2018
29
Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ( 29846533 )
2018
30
Granulomatosis With Polyangiitis Associated With Mumps Viral Infection. ( 29424761 )
2018
31
A New CombinedA VaccineA Against Measles, Mumps, Rubella and Varicella in India. ( 29317560 )
2017
32
Complete Genome Sequences of Mumps and Measles Virus Isolates from Three States in the United States. ( 28818890 )
2017
33
Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Pediatrician's Viewpoint. ( 29317562 )
2017
34
Mumps makes a comeback: What nurses need to know. ( 28027128 )
2017
35
Pancreatic pseudocyst after measles, mumps, and rubella vaccination. ( 28082255 )
2017
36
Utilization and impact of European immunization week to increase measles, mumps, rubella vaccine uptake in Austria in 2016. ( 28797728 )
2017
37
Heat shock protein 90 ensures efficient mumps virus replication by assisting with viral polymerase complex formation. ( 28053100 )
2017
38
Magnetic Resonance Imaging Findings of Mumps Meningoencephalitis with Bilateral Hippocampal Lesions without Preceding Acute Parotitis: A Case Report. ( 28246518 )
2017
39
A case of mumps-related acute encephalopathy with biphasic seizures and late reduced diffusion. ( 28501474 )
2017
40
Ongoing mumps outbreak in Israel, January to August 2017. ( 28877843 )
2017
41
Mumps Virus SH Protein Inhibits NF-I_B Activation by Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and Toll-Like Receptor 3 Complexes. ( 28659487 )
2017
42
Pseudotumoral acute cerebellitis associated with mumps infection in a child. ( 28868306 )
2017
43
Mumps Virus Nucleoprotein and Hemagglutinin-Specific Antibody Response Following a Third Dose of Measles Mumps Rubella Vaccine. ( 29308410 )
2017
44
An outbreak of mumps with genetic strain variation in a highly vaccinated student population in Scotland. ( 28903791 )
2017
45
Campaign Mode MMR Vaccination to Control Outbreak of Mumps in a Highly Vaccinated Population: Evidence-based Medicine viewpoint. ( 29317561 )
2017
46
Severe Complications of Mumps. ( 28891485 )
2017
47
Third Dose of MMR Vaccine for Mumps Control. ( 29239596 )
2017
48
Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. ( 28877026 )
2017
49
The pathogenesis of iodide mumps: A case report. ( 29382013 )
2017
50
A Complication after Percutaneous Nephrolithotomy: Anesthesia Mumps. ( 28928593 )
2017

Variations for Mumps

Expression for Mumps

Search GEO for disease gene expression data for Mumps.

Pathways for Mumps

Pathways related to Mumps according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CD40LG CD46 HLA-DRB1 IFNAR2 IFNG IL10RB
2
Show member pathways
13.85 CD40LG IL10RB IL12RB2 IL2 IRAK1 RIPK1
3
Show member pathways
13.68 CD40LG IFNAR2 IFNG IL10RB IL12RB2 IL2
4
Show member pathways
13.52 IFNAR2 IFNG IL10RB IL12RB2 IL2 RIPK1
5
Show member pathways
13.41 CD40LG IL10RB IL12RB2 IL2 IRAK1 RIPK1
6
Show member pathways
13.29 CD40LG IL10RB IL12RB2 IL2 TNF TNFRSF1A
7
Show member pathways
13.02 IFNAR2 IFNG IL2 IRAK1 RIPK1 STAT1
8
Show member pathways
12.99 IFNAR2 IL2 STAT1 STAT2 TNF TNFRSF1A
9 12.88 IFNAR2 IFNG IL12RB2 IL2 STAT1 STAT2
10
Show member pathways
12.88 CD40LG HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
11
Show member pathways
12.83 IRAK1 IRF2 RIPK1 TNF TNFRSF1A
12
Show member pathways
12.81 IFNG IL2 IRAK1 TNF TNFRSF1A
13
Show member pathways
12.81 CD40LG HLA-DRB1 IFNAR2 IFNG IL10RB IL12RB2
14
Show member pathways
12.76 CD40LG IL2 IRAK1 RIPK1 TNF TNFRSF1A
15
Show member pathways
12.72 CD40LG IFNG RIPK1 STAT1 TNF TNFRSF1A
16
Show member pathways
12.65 IFNG IL10RB IL2 RIPK1 STAT1 TNF
17
Show member pathways
12.6 IFNAR2 STAT1 STAT2 TNF TNFRSF1A
18
Show member pathways
12.6 HLA-DRB1 IFNAR2 IFNG IRF2 STAT1 STAT2
19
Show member pathways
12.58 CD40LG IRAK1 RIPK1 TNF TNFRSF1A
20
Show member pathways
12.54 CD46 HLA-DRB1 IFNAR2 IFNG IL2 IRAK1
21
Show member pathways
12.52 IFNAR2 IFNG IL2 TNF
22
Show member pathways
12.52 HLA-DRB1 IFNG IL12RB2 IL2 STAT1 TNF
23
Show member pathways
12.51 IFNAR2 IFNG IL10RB IL12RB2 IL2 IRF2
24
Show member pathways
12.45 CD40LG IFNG IL2 TNF
25 12.45 HLA-DRB1 IL2 TNF TNFRSF1A
26 12.37 HLA-DRB1 IFNG IL10RB IRAK1 RIPK1
27
Show member pathways
12.36 RIPK1 STAT1 TNF TNFRSF1A
28
Show member pathways
12.34 IFNAR2 IFNG STAT1 STAT2
29
Show member pathways
12.33 IFNG IL12RB2 IL2 STAT1 STAT2 TNF
30
Show member pathways
12.3 IFNG IRAK1 STAT1 TNF
31 12.29 CD40LG RIPK1 TNF TNFRSF1A
32 12.27 HLA-DRB1 IFNG IL10RB IRAK1 STAT1 TNF
33
Show member pathways
12.26 HLA-DRB1 IL10RB IL12RB2 IL2 STAT1
34
Show member pathways
12.25 IL2 STAT1 STAT2 TNF
35
Show member pathways
12.24 IFNAR2 IFNG RIPK1 STAT1 STAT2 TNF
36
Show member pathways
12.22 IFNG IRAK1 STAT1 TNF
37 12.22 IFNG STAT1 TNF TNFRSF1A
38
Show member pathways
12.2 CD40LG HLA-DRB1 IFNG IL10RB IRAK1 STAT1
39
Show member pathways
12.19 RIPK1 TNF TNFRSF1A
40
Show member pathways
12.17 IL2 RIPK1 TNF TNFRSF1A
41
Show member pathways
12.15 IFNG IL10RB IL2 STAT1 STAT2 TNFRSF1A
42 12.13 IFNAR2 RIPK1 STAT1 STAT2 TNF TNFRSF1A
43 12.11 IFNAR2 IFNG STAT1 STAT2 TNF TNFRSF1A
44 12.08 IFNG TNF TNFRSF1A
45
Show member pathways
12.06 IFNG IL2 STAT1
46 12.05 STAT1 STAT2 TNF
47
Show member pathways
12.02 RIPK1 TNF TNFRSF1A
48
Show member pathways
12.02 HLA-DRB1 IFNG IL12RB2 IL2 IRAK1 STAT1
49 12.01 IFNG IL2 TNF
50 11.99 IFNG IL2 TNF

GO Terms for Mumps

Cellular components related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.55 CD40LG CD46 HLA-DRB1 TNF TNFRSF1A
2 plasma membrane GO:0005886 9.36 CD40LG CD46 HLA-DRB1 IFNAR2 IL10RB IL12RB2
3 external side of plasma membrane GO:0009897 9.26 CD40LG HLA-DRB1 IL12RB2 TNF

Biological processes related to Mumps according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.96 IFNAR2 IFNG IL12RB2 TNFRSF1A
2 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.88 IRAK1 RIPK1 TNF TNFRSF1A
3 positive regulation of protein phosphorylation GO:0001934 9.87 IFNG IL2 RIPK1 TNF
4 immune response GO:0006955 9.87 CD40LG HLA-DRB1 IFNG IL10RB IL2 TNF
5 response to virus GO:0009615 9.84 IFNAR2 IFNG TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.83 CD40LG IRAK1 RIPK1 TNF
7 apoptotic signaling pathway GO:0097190 9.81 RIPK1 TNF TNFRSF1A
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IFNG IL2 TNFRSF1A
9 viral process GO:0016032 9.8 CD46 HLA-DRB1 IRAK1 RIPK1 STAT1 STAT2
10 positive regulation of T cell proliferation GO:0042102 9.79 CD40LG CD46 IL2
11 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.78 RIPK1 TNF TNFRSF1A
12 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 IRAK1 STAT1 TNF
13 tumor necrosis factor-mediated signaling pathway GO:0033209 9.77 CD40LG RIPK1 STAT1 TNF TNFRSF1A
14 extrinsic apoptotic signaling pathway GO:0097191 9.73 IFNG RIPK1 TNF
15 interferon-gamma-mediated signaling pathway GO:0060333 9.73 HLA-DRB1 IFNG IRF2 STAT1
16 positive regulation of interferon-gamma production GO:0032729 9.72 IL12RB2 IL2 TNF
17 regulation of tumor necrosis factor-mediated signaling pathway GO:0010803 9.69 RIPK1 TNF TNFRSF1A
18 positive regulation of osteoclast differentiation GO:0045672 9.68 IFNG TNF
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
20 regulation of regulatory T cell differentiation GO:0045589 9.67 IFNG IL2
21 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.66 IFNG STAT1
22 interleukin-35-mediated signaling pathway GO:0070757 9.65 IL12RB2 STAT1
23 positive regulation of programmed cell death GO:0043068 9.65 RIPK1 TNF
24 regulation of type I interferon-mediated signaling pathway GO:0060338 9.65 IFNAR2 STAT1 STAT2
25 positive regulation of regulatory T cell differentiation GO:0045591 9.64 CD46 IL2
26 positive regulation of ceramide biosynthetic process GO:2000304 9.63 TNF TNFRSF1A
27 response to interferon-beta GO:0035456 9.63 IFNAR2 STAT1
28 JAK-STAT cascade GO:0007259 9.63 IFNAR2 STAT1 STAT2
29 defense response to virus GO:0051607 9.63 IFNAR2 IFNG IL10RB IRF2 STAT1 STAT2
30 regulation of establishment of endothelial barrier GO:1903140 9.62 TNF TNFRSF1A
31 necroptotic signaling pathway GO:0097527 9.6 RIPK1 TNF
32 regulation of immunoglobulin secretion GO:0051023 9.58 CD40LG TNF
33 death-inducing signaling complex assembly GO:0071550 9.58 RIPK1 TNF TNFRSF1A
34 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.54 IFNG TNF
35 positive regulation of vitamin D biosynthetic process GO:0060557 9.49 IFNG TNF
36 type I interferon signaling pathway GO:0060337 9.35 IFNAR2 IRAK1 IRF2 STAT1 STAT2
37 cytokine-mediated signaling pathway GO:0019221 9.28 IFNAR2 IL10RB IL12RB2 IL2 IRAK1 STAT1
38 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 IL2 IRF2 RIPK1 STAT1 TNF TNFRSF1A

Molecular functions related to Mumps according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.83 CD40LG CD46 HLA-DRB1 IFNAR2 IFNG IL10RB
2 cytokine activity GO:0005125 9.56 CD40LG IFNG IL2 TNF
3 cytokine receptor activity GO:0004896 9.33 IFNAR2 IL10RB IL12RB2
4 ubiquitin-like protein ligase binding GO:0044389 9.32 STAT1 STAT2
5 tumor necrosis factor receptor binding GO:0005164 8.8 CD40LG STAT1 TNF

Sources for Mumps

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....